Interventions of Interest

  • tolebrutinib (Sanofi)

An independent appraisal committee voted that current evidence on tolebrutinib is not adequate to demonstrate a net health benefit of tolebrutinib compared to best supportive care.

For questions please contact [email protected].

View the Key Stakeholder List.

Final Documents

Final Evidence Report and Meeting SummaryDownload
Report-at-a-GlanceDownload
Final Policy RecommendationsDownload
The ICER Snapshot: for PatientsDownload
Draft Evidence ReportDownload
Response to Public CommentsDownload

ICER’s Senior Vice President of Research, Foluso Agboola, MBBS, MPH:

“There is a large unmet need for effective treatments in non-relapsing SPMS, particularly with the non-active type. Clinical trial evidence suggests that tolebrutinib slows disease progression in patients with non-relapsing SPMS; however, there are still uncertainties about the balance of its overall efficacy and adverse events, as reflected in the voting results of the independent appraisal committee at ICER’s public meeting. Longer-term data will help define the overall net health benefit of tolebrutinib.”